Last updated: February 15, 2026
What is NDC 00904-6948?
NDC 00904-6948 refers to Keytruda (pembrolizumab), a programmed death receptor-1 (PD-1) inhibitor developed by Merck. Approved for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and others, Keytruda is a leading immune checkpoint inhibitor in the oncology market.
Market Size and Trends
Global Oncology Market
The global oncology drugs market was valued at approximately USD 160 billion in 2022. Expected CAGR (Compound Annual Growth Rate) for 2023-2028 is 8%. Keytruda holds a dominant position, with revenue reaching USD 17.2 billion in 2022, representing roughly 11% of the global oncology market.
Keytruda’s Revenue and Market Penetration
- 2022 revenue: USD 17.2 billion (up 20% YoY)[1].
- Main indications include melanoma, NSCLC, lung squamous cell carcinoma, HNSCC, classical Hodgkin lymphoma, and others.
- The drug's broad label expansion has driven its market share growth.
Competitive Landscape
Major competitors: Opdivo (nivolumab, Bristol-Myers Squibb), Atezo (atezolizumab, Genentech), and Tecentriq (atezolizumab, Roche).
- Opdivo’s 2022 revenue: USD 8.3 billion.
- Keytruda maintains a higher market share due to broader indications and stronger clinical data.
Market Drivers
- Increasing cancer prevalence globally.
- Longer patient survival rates due to immune checkpoint inhibitors.
- Expanding indications, including adjuvant settings and combination therapies.
Price Structure and Pricing Trends
Current List Price
- US retail price: Approximately USD 7,000 to USD 13,000 per 200 mg dose, depending on the indication and dosing schedule.
- Cost per treatment course varies accordingly, with typical courses ranging from USD 70,000 to USD 120,000.
Pricing by Indication
- The drug is often priced by treatment duration and indication.
- For metastatic melanoma, the course costs around USD 150,000.
- For NSCLC, costs average USD 100,000 to USD 120,000 per course.
Reimbursement and Payer Coverage
- Insurance coverage is broad in developed countries, with pricing influencing formulary inclusion.
- Public payers, such as Medicare and Medicaid, negotiate rebates and discounts, reducing net prices.
Price Projection and Market Outlook
Short-term (1-3 years)
- Slight price stabilization or modest discounts due to negotiation pressures.
- Continued revenue growth driven by expanded indications and combination therapies.
- Price per dose remains in the USD 7,000 to USD 13,000 range.
Medium-term (3-5 years)
- Introduction of biosimilars or competitive PD-1/PD-L1 agents could exert downward pressure.
- Price reductions of 10-20% may occur if biosimilars penetrate the market.
- Enhanced use in early-stage and adjuvant settings could maintain high volumes.
Long-term (5+ years)
- Potential for significant price erosion contingent on biosimilar development and regulatory approvals.
- Generic entry expected to reduce list prices by up to 50% within a decade.
- Market growth may slow as indications become saturated or as new therapies emerge.
Regulatory and Policy Influences
- Price negotiations in countries with government control (e.g., UK, Canada, Australia) may curtail list prices.
- US pricing may decline as CMS and private payers implement value-based pricing models.
- Patent expiry on some components or manufacturing processes could catalyze biosimilar development.
Strategic Implications
- Merck’s pipeline expansion, with next-generation PD-1/PD-L1 agents and combination therapies, aims to sustain revenue streams.
- Cost management and value demonstration will influence pricing strategies amidst market maturity.
Key Takeaways
- NDC 00904-6948 (Keytruda) remains a leading oncology drug, with 2022 revenues of USD 17.2 billion.
- The drug’s list price ranges from USD 7,000 to USD 13,000 per dose, with treatment courses costing up to USD 150,000.
- Market growth is driven by expanding indications and high unmet needs, but competitive pressures and biosimilars threaten future pricing stability.
- Short-term prices are unlikely to change significantly; in the medium to long term, biosimilar entry could reduce prices by up to 50%.
- Policy, reimbursement strategies, and clinical adoption will significantly shape future market dynamics and pricing.
FAQs
1. How competitive is Keytruda in the PD-1/PD-L1 inhibitor market?
Keytruda dominates due to broader approvals and extensive clinical data, capturing about 60% of the PD-1 market share in 2022, compared to Opdivo’s 30%.
2. Will biosimilars significantly impact Keytruda’s pricing?
Yes. Similar biologics entering the market can lead to price reductions of 30-50%, especially in developed countries with strict price controls.
3. How does indication expansion affect pricing?
Broader indications increase revenue but typically do not lead to price hikes. Instead, they boost volume sales while maintaining stable or slightly varied list prices.
4. Are there geographic differences in pricing?
Yes. US prices are among the highest, with list prices around USD 7,000-13,000 per dose. In countries with government negotiations, prices are usually lower.
5. What are the key factors that could alter the market outlook?
Regulatory decisions on biosimilar approval, advances in competing therapies, and changes in healthcare reimbursement policies all influence future pricing and market share.
References
- Merck Annual Report 2022.
- IQVIA Market Data 2022.
- EvaluatePharma World Preview 2023.
- U.S. FDA Database.
